14 February 2020
A study published in JAD from researchers at McGill University led by Dr. Claudio Cuello of the Department of Pharmacology and Therapeutics, has shown that, when given in a formulation that facilitates passage to the brain, lithium in doses up to 400 times lower than what is currently being prescribed for mood disorders is capable of both halting signs of advanced Alzheimer's pathology such as amyloid plaques and of recovering lost cognitive abilities.
23 January 2020
Mild Cognitive Impairment: ISS Produces the First Epidemiological Estimation of the Phenomenon Among Migrants in Europe
In a study published in the Journal of Alzheimer's Disease, ISS researchers estimated about 680,000 cases of mild cognitive impairment (MCI) in a total of 12,730,960 migrants, aged between 60 and 89 years, living in the European Union (EU) in 2018.
20 January 2020
A new study published in the Journal of Alzheimer's Disease (JAD) supports a growing body of research that links human exposure to aluminum with Alzheimer's disease (AD). Researchers found significant amounts of aluminum content in brain tissue from donors with familial AD. The study also found a high degree of co-location with the amyloid-beta protein, which leads to early onset of the disease.
22 December 2019
To the medical community’s surprise, several studies from the US, Canada, and Europe suggest a promising downward trend in the incidence and prevalence of dementia. Important risk factors for dementia, such as mid-life obesity and mid-life diabetes, have been increasing rapidly, so the decline in dementia incidence is particularly perplexing.
27 November 2019
New Study Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-Moderate Alzheimer's Disease
TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer’s disease. These results showed that the drug produced concentration-dependent effects on cognitive decline and brain atrophy.
26 November 2019
Miharu Nakanishi, Chief Researcher of Tokyo Metropolitan Institute of Medical Science, and her colleagues finds that psychological well-being at 52 years were prospectively associated with cognitive function at 69 years. The authors used data in women from the British 1946 birth cohort in the Medical Research Council’s National Survey of Health and Development. There was a significant association between greater personal growth and lower self-acceptance at 52 years, and better cognition at 69 years.
20 November 2019
Oligomerix, Inc. and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD. The study showed that the compound blocked tau self-association, which is the earliest step in the toxic tau aggregation cascade, and inhibited the downstream events that lead to tau fibril formation.
14 November 2019
University of Canberra researchers have shown that art gallery programs can improve the wellbeing of people living with dementia – and they’ve backed it up by testing study participants’ saliva. Published in the Journal of Alzheimer’s Disease, the UC study monitored new participants of the National Gallery of Australia’s (NGA) Art and Dementia program over six weeks. The NGA program has been running for more than 12 years and has demonstrated anecdotal and observational benefits, now backed up by UC research.
31 October 2019
A new study from Columbia University found that a higher level of education protected against cognitive decline in black people with a gene linked to Alzheimer's disease.
28 October 2019
The way people walk is an indicator of how much their brains, as well as their bodies, are aging. Scientists reporting in a JAD special supplement say that gait disorders, particularly slowing gait, should be considered a marker of future cognitive decline. They propose testing motor performance as well as cognitive performance in older adults with mild cognitive impairments.